Apollomics Inc. Class A Ordinary Shares Asset Resilience Ratio
Apollomics Inc. Class A Ordinary Shares asset resilience ratio. Apollomics Inc. Class A Ordinary Shares (APLM) has an Asset Resilience Ratio of 0.11% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See APLM cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Apollomics Inc. Class A Ordinary Shares (2019–2024)
Asset resilience ratio of Apollomics Inc. Class A Ordinary Shares from 2019 to 2024. This chart shows how Apollomics Inc. Class A Ordinary Shares's Asset Resilience Ratio has changed over time. Read APLM total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Apollomics Inc. Class A Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see APLM asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.00K | 0.11% |
| Total Liquid Assets | $14.00K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Apollomics Inc. Class A Ordinary Shares maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Apollomics Inc. Class A Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Apollomics Inc. Class A Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Apollomics Inc. Class A Ordinary Shares Asset Resilience Ratio by Year (2019–2024)
Apollomics Inc. Class A Ordinary Shares asset resilience ratio by year from 2019 to 2024. The table below shows the annual Asset Resilience Ratio data for Apollomics Inc. Class A Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | $14.00K | $13.10 Million | -10.29pp |
| 2023-12-31 | 10.40% | $5.76 Million | $55.39 Million | -18.29pp |
| 2022-12-31 | 28.69% | $21.94 Million | $76.47 Million | -9.99pp |
| 2021-12-31 | 38.68% | $47.74 Million | $123.44 Million | +24.71pp |
| 2020-12-31 | 13.97% | $23.74 Million | $169.94 Million | -31.11pp |
| 2019-12-31 | 45.08% | $35.63 Million | $79.05 Million | -- |
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung… Read more